Menu
Home
GPcardio CVD, CKD & T2D About EPCCS About IPCCS NCD Academy EACH WONCA World 2025
EPCCS
About EPCCS Connected Societies GPcardio About IPCCS
Education
Lipid Management in ... Cardio Renal Update Cardiovascular Updat... The EU Cardiovascula... Cardiovascular Disea... Managing CV risk in ...
Resources
Practice Guidance Meeting reports STRATIFYHF Recent News Video updates WONCA World 2025
Literature
Left Atrial Appendag... 26 Mar. Novel cardiovascular... 26 Mar. Systemic Inflammatio... 24 Mar. Use of Coronary Arte... 16 Mar. 2026 ACC/AHA Guideli... 13 Mar. Off-label underdosin... 12 Mar. Semaglutide promotes... 9 Mar. Effect of baxdrostat... 7 Mar. More Literature

Oct. 4, 2022

2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

A Report of the American College of Cardiology Solution Set Oversight Committee.

Donald M Lloyd-Jones, Pamela B Morris, Christie M Ballantyne et al. - Journal of the American College of Cardiology

The 2022 ACC Expert Consensus updated the decision pathway for nonstatin lipid-lowering therapies, integrating evidence on bempedoic acid and inclisiran alongside ezetimibe and PCSK9 monoclonal antibodies. The document provided practical algorithms for escalating therapy to achieve LDL-cholesterol targets.

Source